Why Model Medicines needs to ‘discover new colors’ in its AI drug discovery quest
“Outliers are what you're going for,” Model Medicines CEO Daniel Haders, Ph.D., told Fierce to explain the company's AI-driven drug development strategy.
“Outliers are what you're going for,” Model Medicines CEO Daniel Haders, Ph.D., told Fierce to explain the company's AI-driven drug development strategy.